Entering text into the input field will update the search result below

Fate Therapeutics' (FATE) CEO Scott Wolchko on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2017 Earnings Conference Call March 5, 2018 5:00 PM ET


Scott Wolchko - President and Chief Executive Officer

Chris Storgard - Chief Medical Officer

Dan Shoemaker - Chief Scientific Officer


Michael Schmidt - Leerink Partners

Edward Tenthoff - Piper Jaffray

Jim Birchenough - Wells Fargo Securities

David Nierengarten - Wedbush Securities

Ren Benjamin - Raymond James


Welcome to Fate Therapeutics Fourth Quarter 2017 Financial Results Conference Call. At this time all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Fate webcast at fatetherapeutics.com As a reminder, today’s conference call is being recorded. I would now like to introduce Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Scott Wolchko

Thank you. Good afternoon and thanks everyone for joining us for the Fate Therapeutics fourth quarter 2017 financial results call. Shortly after 4 PM Eastern Time today, we issued a press release with these results, which can be found on the Investors & Media section of our website under Press Releases. In addition, our Form 10-K for the year ended December 31, 2017 is being filed shortly today and can be found on the Investors & Media section of our website under Financial Information.

Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and the responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.

Please see the forward-looking statement disclaimer on the company’s earnings press release issued after the close of market today, as well

Recommended For You

Comments (1)

Bright spot profile picture
I believe FATE will make it to 24$ this year. Top notch research and results.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About FATE

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on FATE

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.